Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.63 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | RHEB | Q15382 | 1/20 | 0.62 |
| ▸ | SCD | O00767 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ridinilazole SCHEMBL29785777 | 0.93 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| Ridinilazole SCHEMBL19235713 | 0.93 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| Ridinilazole SCHEMBL29613225 | 0.93 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| Ridinilazole SCHEMBL413723 | 0.93 | ALDH1A1 (0.66) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| Ridinilazole SCHEMBL29379856 | 0.93 | ALDH1A1 (0.66) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| SCHEMBL14859469 | 0.88 | NPC1 (0.52) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| SCHEMBL14859468 | 0.88 | NPC1 (0.52) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| SCHEMBL14859401 | 0.88 | NPC1 (0.52) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| SCHEMBL16498433 | 0.87 | ALDH1A1 (0.57) | NPC1RAB9AKDM4EALDH1A1PKN1 | |
| SCHEMBL16497674 | 0.86 | PKN1 (0.51) | NPC1RAB9AKDM4EALDH1A1PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763925-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2017-09-19 | — | — | US | claimed |
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2016-06-30 | — | — | US | claimed |
| US-20200290995-A1 | Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts | SANDOZ AG (CH) | 2020-09-17 | — | — | US | disclosed |
| WO-2019068383-A1 | PROCESS FOR THE PREPARATION OF RIDINILAZOLE USING ACID ADDITION SALTS | SANDOZ AG (CH) | 2019-04-11 | — | — | WO | disclosed |
| US-9763925-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | NPC1 512/4885RAB9A 1670/4885KDM4E 4769/4885 |
| US-20200290995-A1 | Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts | CYP3A5, CYP3A7, CYP3A4 | NPC1 1676/4885RAB9A 1702/4885KDM4E 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.